Disclosed are pharmaceutical compositions comprising ceftaroline fosamil for treatment of a bacterial infection, wherein the composition comprises from about 200 mg to about 800 mg of ceftaroline fosamil, about 0.6 to about 0.7 equivalents (w/w) of the pH stabilizer L-arginine as compared to ceftaroline fosamil, less than 2% of the L-arginine adduct of formula I or II, and the composition provides a mean AUC for ceftaroline in patients with a creatinine clearance from about 50 to about 80 ml/min of about 1.2 times greater than the mean AUC for ceftaroline in patients with a creatinine clearance of greater than about 80 ml/min. Also disclosed is the use of the pharmaceutical composition in the preparation of a medicament for the treatment of a bacterial infection, particularly where the infection is a complicated skin and skin structure infection or community-acquired bacterial pneumonia.
